Compare · AZN vs INSM
AZN vs INSM
Side-by-side comparison of AstraZeneca PLC (AZN) and Insmed Incorporated (INSM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and INSM operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $263.10B, about 9.7x INSM ($27.06B).
- Over the past year, AZN is down 9.9% and INSM is down 6.3% - INSM leads by 3.6 points.
- AZN has been more active in the news (14 items in the past 4 weeks vs 9 for INSM).
- Both have 25 recent analyst ratings on file.
- Company
- AstraZeneca PLC
- Insmed Incorporated
- Price
- $169.66+1.75%
- $123.85-0.03%
- Market cap
- $263.10B
- $27.06B
- 1M return
- -0.09%
- +18.36%
- 1Y return
- -9.89%
- -6.34%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 14
- 9
- Recent ratings
- 25
- 25
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Insmed Incorporated
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Latest AZN
- TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
- Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
Latest INSM
- Insmed to Present at September 2026 Investor Conferences
- BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
- Director Sharoky Melvin Md sold $637,650 worth of shares (5,000 units at $127.53) (SEC Form 4)
- Chief Operating Officer Adsett Roger sold $31,964,810 worth of shares (239,850 units at $133.27) and exercised 239,850 shares at a strike of $20.45 (SEC Form 4)
- Chief Medical Officer Flammer Martina M.D. exercised 27,173 shares at a strike of $21.20 and sold $3,494,838 worth of shares (27,173 units at $128.61) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Insmed Incorporated
- Insmed Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update
- SEC Form 10-Q filed by Insmed Incorporated
- Chair and CEO Lewis William exercised 10,700 shares at a strike of $24.94 and sold $1,134,890 worth of shares (10,700 units at $106.06) as part of a pre-agreed trading plan (SEC Form 4)